How Long Does It Take for Serrapeptase to Dissolve Scar Tissue?

No reliable clinical timeline exists for serrapeptase dissolving scar tissue, because the evidence that it dissolves scar tissue in humans at all is thin. Serrapeptase is a proteolytic enzyme with documented anti-inflammatory and fibrin-degrading properties, and it does reduce swelling and pain in some short-term clinical settings. But the specific claim that it breaks down established scar tissue and the question of how long that takes outpaces what the research actually shows. Understanding where the evidence is solid and where it trails off matters if you are considering this supplement for scars.

What Serrapeptase Does and Does Not Break Down

Serrapeptase is a metalloprotease enzyme originally isolated from bacteria found in the intestines of silkworms. Its documented biological activities include anti-inflammatory, analgesic, and fibrinolytic effects, along with the ability to break down biofilms produced by certain bacteria.¹ The fibrinolytic part is the piece most relevant to the scar tissue question. Fibrin is the protein that forms the structural scaffolding of blood clots, and it also plays a role in wound healing and, eventually, scar formation. Serrapeptase can break down fibrin.

Here is where it gets complicated. Mature scar tissue is not just fibrin. Scars are primarily made of collagen, a much tougher and more structured protein that your body deposits over weeks and months during healing. While fibrin is part of the early wound-healing matrix, the collagen that replaces it is the dominant component of any scar you can see or feel. There is no strong evidence from human trials that oral serrapeptase breaks down established collagen-rich scar tissue. The fibrinolytic activity is real, but fibrinolysis and scar dissolution are not the same thing.

How Quickly It Works on Inflammation and Swelling

Where serrapeptase does show measurable effects in a somewhat clear timeline is in reducing post-surgical inflammation and swelling. After oral intake, serrapeptase is absorbed through the intestine and reaches peak blood levels within about 15 to 30 minutes, remaining detectable for up to six hours. It tends to concentrate in inflamed tissue at higher levels than in plasma.²

In a study of patients who had their lower wisdom teeth surgically removed, those given serrapeptase had significantly less cheek swelling and pain by postoperative days two, three, and seven compared to a control group.³ A separate trial in orthopedic trauma patients found that a high-dose serrapeptase group had significantly lower pain scores starting from day three, with the difference persisting through day fifteen.⁴ So for acute swelling and pain after surgery or injury, serrapeptase appears to produce noticeable effects within a few days, with improvements continuing over one to two weeks.

This is important context because many people take serrapeptase for scars after reading about its anti-inflammatory and anti-swelling effects. Those effects are real in the short term after tissue injury. But reducing fresh postoperative swelling is a different biological process from breaking down an old, established scar.

Why Acute Inflammation Results Do Not Predict Scar Dissolution

Scar tissue formation happens in stages. In the first days after an injury, fibrin and inflammatory fluids accumulate at the wound site. Over the following weeks, your body lays down collagen fibers to create a strong repair. Over months, those fibers remodel and mature. An old scar that is several months or years old is a dense, cross-linked collagen structure with its own blood supply. It is biologically very different from the loose fibrin-and-fluid mixture that forms in the first few days of healing.

Serrapeptase’s demonstrated ability to thin inflammatory fluids and break down fibrin explains why it helps with fresh post-surgical swelling. It does not explain how it would dismantle the collagen architecture of a mature scar. Some proponents argue that by reducing inflammation, serrapeptase creates conditions that allow the body to remodel scar tissue more effectively over time. That is a plausible hypothesis, but it remains largely untested in rigorous human studies.

A Direct Test That Came Up Empty

One of the most instructive pieces of evidence comes from a study that specifically looked at whether serrapeptase prevents fibrosis, the very process of scar-like tissue formation. In patients who underwent liposuction for lipedema, oral serrapeptase supplementation did not demonstrate measurable efficacy in preventing postoperative fibrosis or improving patient-reported outcomes.⁵ The researchers concluded that the findings do not support routine use of serrapeptase in that clinical setting.

This is significant because fibrosis after liposuction is essentially scar tissue formation inside the body, exactly the kind of target serrapeptase would need to affect if it were going to work on scars. The fact that it failed to show a measurable effect in this context is a meaningful data point. It does not definitively prove serrapeptase never helps with any type of fibrotic tissue, but it does show that the assumption of antifibrotic efficacy does not hold up in at least one well-defined surgical scenario.

Typical Doses and Durations in Studies

If you look at how serrapeptase is actually used in clinical trials, the dosing and duration vary considerably, which itself is a problem for anyone trying to figure out how long to take it. In the wisdom tooth surgery study, treatment was short-term, covering just the first week after surgery. The orthopedic trauma study tracked outcomes through day fifteen. A study on inflammatory acne used a combination of curcumin and serrapeptase at a total daily dose of 30 mg of serrapeptase for four weeks, which the researchers described as an adequate period to observe initial clinical response.⁶

Consumer supplement labels commonly suggest doses ranging from 60,000 to 120,000 SPU (serrapeptase activity units) per day, sometimes higher, often for periods of several weeks to months for scar-related goals. These recommendations are not based on clinical trial evidence for scar tissue specifically. They are extrapolated from the shorter-term anti-inflammatory studies combined with general reasoning about how long tissue remodeling takes. That extrapolation is the gap that has not been bridged by research.

Anecdotal reports online frequently mention timelines of three to six months for people taking serrapeptase with the goal of softening or reducing scars. Some report taking it for a year or longer. These timelines are not verified by controlled studies. Any scar naturally changes over time anyway, softening and fading on its own, which makes it very difficult to tell whether serrapeptase is responsible for improvements someone notices over months of use.

The Quality Problem in Serrapeptase Research

A systematic review of the existing serrapeptase evidence found that the studies supporting its use as an anti-inflammatory and pain-relieving agent are generally of poor methodology. Most are small, placebo-controlled trials with limited sample sizes. In some studies, the dose and duration of treatment were not clearly specified, and outcomes were not well defined. Data on long-term safety and tolerability is lacking.⁷

This matters because the people most interested in serrapeptase for scars are often looking for something to help with keloids, hypertrophic scars, surgical adhesions, or post-injury fibrosis. These are conditions where you would want strong, well-designed trials before committing to months of supplementation. What exists instead are mostly short-term, small studies focused on acute swelling and pain, not on long-term scar remodeling. The leap from “reduced cheek swelling after tooth extraction” to “dissolves keloid scars over three months” is bigger than the marketing suggests.

Safety and Side Effects

Serrapeptase is generally considered well tolerated, but the safety data is limited. Reported adverse effects are rare and based mostly on individual case reports rather than systematic monitoring. These include bullous pemphigoid (a blistering skin condition), pneumonitis, acute eosinophilic pneumonia, and Stevens-Johnson syndrome when serrapeptase was combined with the anti-inflammatory drug diclofenac.⁸ These are uncommon, but the fact that the systematic review noted a lack of safety and tolerability data across studies means the true incidence of side effects is not well characterized.

Because serrapeptase has fibrinolytic activity, it thins blood clotting to some degree. If you are taking anticoagulant medications or have a bleeding disorder, combining serrapeptase with your existing treatment could be risky. The enzyme also concentrates in inflamed tissue, which means its effects may be more pronounced in areas of active healing. Anyone considering serrapeptase after surgery should discuss it with their surgeon, particularly because the evidence for preventing surgical fibrosis is not encouraging.

The Inflammation Connection That Does Hold Up

Where serrapeptase seems to have its most defensible role is in reducing the inflammatory component of tissue damage, which can indirectly influence how scars develop in the first place. In animal studies, serrapeptase suppressed vascular inflammation by inhibiting the production of inflammatory signaling molecules and reducing oxidative stress in blood vessel tissue.⁹ If excess inflammation during the early healing phase leads to worse scarring, then reducing that inflammation could theoretically result in a less pronounced scar. This is the most biologically plausible pathway by which serrapeptase might influence scar outcomes.

But this mechanism would only apply during the active healing window, roughly the first few weeks after an injury or surgery, when inflammatory processes are still driving tissue formation. Taking serrapeptase months or years after a scar has matured would not benefit from this mechanism, because the inflammatory phase is long over. The scar has already formed, and the question becomes whether serrapeptase can actively dismantle it. On that question, the evidence is essentially absent.

Serrapeptase as a Biofilm Breaker

One area where serrapeptase research is genuinely advancing is in breaking down bacterial biofilms, the protective matrices that bacteria build around themselves. Studies have shown that serrapeptase can reduce biofilm formation by more than 90 percent in some laboratory conditions, disrupting the structural components bacteria use to anchor themselves.¹⁰ The enzyme appears to work through two distinct mechanisms: one part of the molecule breaks down pre-formed biofilms through direct protein degradation, while another part inhibits new biofilm development.¹¹

This is relevant to scarring in an indirect way. Chronic infections with biofilm-producing bacteria can sustain inflammation and contribute to poor wound healing, which in turn can worsen scarring. If serrapeptase helps clear biofilms and allows antibiotics to work more effectively, it could indirectly improve healing outcomes in infected wounds. This is not the same as dissolving an existing scar, but it represents a legitimate and well-supported biological activity that intersects with wound healing in a meaningful way.

What Natural Scar Remodeling Looks Like Without Serrapeptase

To evaluate any scar treatment, you need to know the baseline: scars change on their own. Most surgical or traumatic scars continue to mature and remodel for twelve to eighteen months after the initial injury. During that window, a scar naturally becomes softer, flatter, and less red or purple as the body reorganizes collagen fibers and blood supply recedes. Many people who start taking serrapeptase a few months after an injury and report improvement at the six-month or twelve-month mark may simply be observing normal scar maturation. Without a controlled comparison, there is no way to separate the supplement’s effect from the body’s natural remodeling process.

Keloid and hypertrophic scars are different. These represent abnormal wound healing where the body overproduces collagen, and they do not follow the normal remodeling timeline. Keloids in particular can continue to grow for years and rarely resolve on their own. If serrapeptase could genuinely break down the excess collagen in keloid scars, that would be a striking finding. But there are no published clinical trials testing serrapeptase specifically on keloid or hypertrophic scars.

Supplement Quality and What You Are Actually Getting

A practical concern that rarely comes up in the scar-tissue conversation is product quality. Serrapeptase is sold as a dietary supplement, which means it is not regulated with the same rigor as a pharmaceutical drug. The enzyme is sensitive to stomach acid and typically requires enteric coating to survive passage through the stomach and be absorbed in the intestine. Products with poor coating may deliver very little active enzyme to the bloodstream. There is no standardized manufacturing process across brands, and the potency measured in SPU on the label may not reflect what is biologically available after you swallow the capsule.

If you are going to try serrapeptase, choosing an enteric-coated product from a manufacturer that uses third-party testing is a reasonable precaution. Taking it on an empty stomach, as most products recommend, maximizes absorption because food in the stomach can degrade the enzyme before the coating dissolves. But even with a high-quality product, you are still working with an enzyme whose scar-tissue effects are unproven in humans. The absorption pharmacokinetics are established, the downstream scar-dissolving claim is not.

Internal Adhesions and Post-Surgical Scarring

Some people take serrapeptase specifically for internal adhesions, the bands of scar-like tissue that can form between organs after abdominal or pelvic surgery. Adhesions can cause pain, bowel obstruction, and fertility problems. They are made of the same collagen-rich fibrous tissue as external scars, and they present the same challenge for serrapeptase: the enzyme’s fibrinolytic activity targets fibrin, not mature collagen.

The liposuction study mentioned earlier is the closest available test of this idea, and its results were negative. No other published clinical trial has specifically examined whether oral serrapeptase reduces or prevents abdominal adhesions. Some naturopathic practitioners recommend serrapeptase for adhesions based on its broader anti-inflammatory profile, but this remains a recommendation without clinical trial support. Given that adhesion-related complications can be serious, relying on an unproven supplement rather than seeking surgical or physical therapy options when adhesions cause symptoms is not a well-supported approach.